Shiv Texchem PB Ratio

Shiv Texchem Ltd Price to Book Ratio

The Shiv Texchem Ltd Price to Book Ratio is a key financial metric used by investors to evaluate Shiv Texchem Ltd's valuation, profitability, and overall financial performance. Tracking the Shiv Texchem Ltd Price to Book Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.

Shiv Texchem Ltd (NSE: , BSE: 544272) is currently trading at ₹114.10, with a market capitalization of ₹2.64B. As a leading company in the Distribution services sector and Wholesale distributors industry, monitoring the Shiv Texchem Ltd Price to Book Ratio is essential for fundamental analysis.

Shiv Texchem Ltd Price to Book Ratio Current Value

The current Shiv Texchem Ltd Price to Book Ratio stands at 1.71.

The latest Shiv Texchem Ltd Price to Book Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.

Shiv Texchem Ltd Price to Book Ratio Historical Trend

The Shiv Texchem Ltd Price to Book Ratio has shown the following historical trend:

• 2024: 1.71
• 2023: 0
• 2022: 0
• 2021: 0

The recent rise in Shiv Texchem Ltd Price to Book Ratio suggests strengthening valuation trends and improving market sentiment.

What Shiv Texchem Ltd Price to Book Ratio Indicates for Investors

The Shiv Texchem Ltd Price to Book Ratio plays a crucial role in understanding the company's financial health and valuation.

The P/B ratio shows how the market values company assets relative to book value.

Shiv Texchem Ltd Price to Book Ratio Analysis Summary

The Shiv Texchem Ltd Price to Book Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Shiv Texchem Ltd Price to Book Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.

Regular tracking of Shiv Texchem Ltd Price to Book Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.